Brief: China Biotech Services Enters Master Collaboration Agreement With Stella Pharma
12/08/2026 01:56
BRIEF-China Biotech Services Enters Master Collaboration Agreement With Stella Pharma Aug 12 (Reuters) - China Biotech Services Holdings Ltd 8037.HK:
ENTERS MASTER COLLABORATION AGREEMENT WITH STELLA PHARMA ON AUG 11, 2026
STELLA PHARMA GRANTS EXCLUSIVE ROYALTY-FREE LICENSE TO CO TO DEVELOP STEBORONINE IN THE PRC
AGREEMENT EXPIRES IF STELLA PHARMA DOES NOT OBTAIN NMPA APPROVAL WITHIN 10 YEARS
Further company coverage: 8037.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on China Biotech Services Holdings
See all newsBrief: China Biotech Services Enters Cooperation Agreement
Brief: China Biotech Services Says HY Revenue From Cont Ops Hk$37.23 Million
Brief: China Biotech Services Expects HY Net Profit Of Not Less Than HK$15.0 MLN
Brief: China Biotech Services Enters Master Collaboration Agreement With Stella Pharma
Brief: China Biotech Services Says BGI Songhe Advances RMB30 Million Loan To Pengbo (Hainan)